Philip Murphy, MD, Beaumont Hospital, Dublin, Ireland, updates us on an ongoing Phase Ib trial being conducted in Ireland, in patients with relapsed/refractory (R/R) multiple myeloma, looking at daratumumab, pomalidomide, cyclophosphamide, and dexamethasone in combination. Prof. Murphy explains that previous studies have shown that using cyclophosphamide in combination with a monoclonal antibody improves immune responses. He also comments on another study which will use next generation sequencing (NGS) to look for measurable residual disease (MRD) and gene expression profiles in newly diagnosed, younger patients with multiple myeloma who will undergo autologous stem cell transplantation (autoSCT). This interview was recorded virtually.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.